Follow up studies with in vivo [ 13 C 6 ]-glucose tracing on liver and kidney 24 h after AKI revealed 4 major findings: (1) increased flux through glycolysis and the tricarboxylic (TCA) cycle in both kidney and liver
however, the model developed in this paper maintains a consistent lead in every category, particularly in terms of G-measure and precision
It undergoes analytical verification to ensure purity and consistency
Chem Eng News (2019), 123
Dose volume: 250 mcg 5,000 mcg/mL = 0.05 mL
[4] Similarly, SURPASS-4, which specifically enrolled patients at high cardiovascular risk, demonstrated a numerical reduction in MACE with tirzepatide compared to insulin glargine, suggesting potential cardiovascular benefit, though definitive conclusions await the dedicated outcomes trial